| 000 | 05544cam a2200457Mi 4500 | ||
|---|---|---|---|
| 999 |
_c95068 _d95068 |
||
| 001 | 95068 | ||
| 003 | ES-MaUEC | ||
| 005 | 20240112094528.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 161202s2017 sz a ob 001 0 eng d | ||
| 020 |
_a3319483609 _q(electronic book) |
||
| 020 |
_a9783319483603 _q(electronic bk.) |
||
| 020 | _z3319015796 | ||
| 020 | _z3319483595 | ||
| 020 | _z9783319483597 | ||
| 035 |
_a(OCoLC)966563464 _z(OCoLC)964585818 _z(OCoLC)964931388 _z(OCoLC)974651424 _z(OCoLC)981099330 _z(OCoLC)1005810185 |
||
| 040 |
_aYDX _cYDX _dOCLCO _dN$T _dGW5XE _dIDEBK _dOCLCA _dOCLCF _dN$T _dAZU _dUAB _dOCLCO _dCOO _dN$T _dOCLCO _dUPM _dIOG _dOCLCO _dVT2 _dMERER _dESU _dZ5A _dOCLCO _dJBG _dIAD _dOCLCO _dICW _dOCLCO _dICN _dOCLCQ _dOCLCO _dOTZ _dOCLCQ _dOCLCO _dJG0 _dOCLCO _dU3W _dOCLCO _dOCLCA _dES-MaUEC _bspa |
||
| 050 | 4 |
_aRC270.3.T84 _bD358 2017 EB |
|
| 100 | 1 |
_aDakubo, Gabriel D., _eautor _996747 |
|
| 245 | 1 | 0 |
_aCancer Biomarkers in Body Fluids : _bBiomarkers in Circulation _cGabriel D. Dakubo. |
| 264 | 1 |
_aCham, Switzerland _bSpringer _c[2017] |
|
| 300 |
_a1 recurso en línea (xix, 519 páginas) _bilustraciones (algunas a color) |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 500 | _aSpringerLink | ||
| 504 | _aIncluye referencias bibliográficas e índice | ||
| 505 | 0 | _aPreface; Contents; About the Author; Chapter 1: Melanoma Biomarkers in Circulation; Key Topics; 1.1 Introduction; 1.2 Screening Recommendations for Melanoma; 1.3 Molecular Pathology of Melanoma; 1.3.1 BRAF Mutations in Melanoma; 1.3.2 RAS Mutations in Melanoma; 1.3.3 Alterations in Cell Cycle Control Genes in Melanoma; 1.3.4 TP53 Mutations in Melanoma; 1.3.5 KIT Mutations in Melanoma; 1.3.6 MITF Mutations in Melanoma; 1.3.7 PI3K Pathway Alterations in Melanoma; 1.3.8 Molecular Subtypes of Melanoma; 1.3.9 Molecular Progression Model of Melanoma; 1.4 Circulating Melanoma Biomarkers. | |
| 505 | 8 | _a1.4.1 Circulating Melanoma Cell-Free Nucleic Acid Biomarkers1.4.2 Circulating Melanoma Epigenetic Biomarkers; 1.4.3 Circulating Melanoma Genetic Biomarkers; 1.4.3.1 Mutations as Circulating Melanoma Biomarkers; 1.4.3.2 Circulating MSA as Melanoma Biomarkers; 1.4.4 Circulating Melanoma Coding RNA Biomarkers; 1.4.5 Circulating Melanoma Noncoding RNA Biomarkers; 1.4.6 Circulating Melanoma Protein Biomarkers; 1.4.6.1 Serum S100beta as Melanoma Biomarker; 1.4.6.2 Serum LDH as Melanoma Biomarker; 1.4.6.3 Serum MIA as Melanoma Biomarker; 1.4.6.4 Serum VEGF as Melanoma Biomarker. | |
| 505 | 8 | _a1.4.6.5 Serum Levodopa to l-Tyrosine Ratio as Melanoma Biomarker1.4.6.6 Serum Cysteinyldopa as Melanoma Biomarker; 1.4.6.7 Serum Autoantibodies as Melanoma Biomarkers; 1.4.6.8 Circulating Melanoma Proteomic Biomarkers; 1.4.7 Circulating Melanoma Cells; 1.4.7.1 Molecular Approaches to CMCs; 1.4.7.2 CMCs in Advanced Stage III and IV Melanoma; 1.4.7.3 CMCs in Uveal Melanoma; 1.4.8 Melanoma Extracellular Vesicles; 1.4.9 Summary; References; Chapter 2: Head and Neck Cancer Biomarkers in Circulation; Key Topics; 2.1 Introduction; 2.2 Screening Recommendations for HNC. | |
| 505 | 8 | _a2.3 The Need for Noninvasive Screening Tests for HNC2.4 Molecular Pathology of HNC; 2.4.1 Molecular Classification of HNC; 2.4.2 Molecular Pathology of HPV-Positive HNC; 2.4.3 Specific Genetic Alterations in HNC; 2.4.3.1 EGFR Alterations in HNC; 2.4.3.2 TGFbeta Pathway Alterations in HNC; 2.4.3.3 PI3K/AKT Pathway Alterations in HNC; 2.4.3.4 TP53 Alterations in HNC; 2.4.3.5 Cell Cycle Gene Alterations in HNC; 2.4.3.6 MET Alterations in HNC; 2.4.3.7 Telomere Alterations in HNC; 2.5 Circulating HNC Biomarkers; 2.5.1 Circulating Cell-Free Nucleic Acids as HNC Biomarkers. | |
| 505 | 8 | _a2.5.2 Circulating HNC Epigenetic Biomarkers2.5.3 Circulating HNC Noncoding RNA Biomarkers; 2.5.3.1 Oncomirs and Tumor Suppressormirs in HNC; 2.5.3.2 Circulating HNC miRNA Biomarkers; 2.5.4 Circulating HNC Serum Protein Biomarkers; 2.5.5 Circulating HNC Cells; 2.5.5.1 Methodologies for CHNCC Analysis; 2.5.5.2 CHNCCs as Staging Biomarkers; 2.5.5.3 CHNCCs as Prognostic Biomarkers; 2.5.5.4 CHNCCs as Predictive Biomarkers; 2.5.5.5 Induction of CHNCCs by Clinical Interventions; 2.5.6 Circulating HPV-Positive HNC Biomarkers; 2.5.7 HNC Extracellular Vesicles; 2.6 Nasopharyngeal Carcinoma. | |
| 520 | 3 | _aThis book examines in depth the evidence, clinical applications and potential cancer signatures in the circulation and discusses alterations in circulating cell-free nucleic acids, and circulating tumor DNA, as well as the epigenome, genome, transcriptome (coding and noncoding), proteome (both traditional serum proteins and proteomic profiles) and metabolome. Further, it highlights the clinical applications of circulating tumor cells for each cancer type and addresses the emerging importance of extracellular vesicular contents, including miRNA, oncogenes and drug resistant factors. As such, it offers a valuable reference guide for cancer researchers, oncologists, clinicians, surgeons, medical students, oncology nurses, diagnostic laboratories, and the pharmaceutical industry. | |
| 988 | _aEBOOK, asignarmaterias, EBSPRINGER_2017B | ||
| 650 | 7 |
_aMarcadores tumorales _2embne _9144360 |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-48360-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b02/2018 _dz _e- _zSI |
||